Paloma Partners Management Co lifted its position in Hologic (NASDAQ:HOLX) by 174.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 33,846 shares of the medical equipment provider’s stock after purchasing an additional 21,494 shares during the quarter. Paloma Partners Management Co’s holdings in Hologic were worth $1,447,000 at the end of the most recent reporting period.
A number of other hedge funds also recently made changes to their positions in HOLX. Global X MANAGEMENT CO LLC boosted its stake in Hologic by 16.6% during the third quarter. Global X MANAGEMENT CO LLC now owns 13,944 shares of the medical equipment provider’s stock worth $512,000 after buying an additional 1,982 shares during the period. Toronto Dominion Bank boosted its stake in Hologic by 12.1% during the third quarter. Toronto Dominion Bank now owns 106,369 shares of the medical equipment provider’s stock worth $3,902,000 after buying an additional 11,520 shares during the period. Los Angeles Capital Management & Equity Research Inc. boosted its stake in Hologic by 1,234.5% during the third quarter. Los Angeles Capital Management & Equity Research Inc. now owns 158,694 shares of the medical equipment provider’s stock worth $5,822,000 after buying an additional 146,802 shares during the period. Rhumbline Advisers boosted its stake in Hologic by 4.8% during the third quarter. Rhumbline Advisers now owns 574,802 shares of the medical equipment provider’s stock worth $21,089,000 after buying an additional 26,337 shares during the period. Finally, Quantbot Technologies LP boosted its stake in Hologic by 3,975.5% during the third quarter. Quantbot Technologies LP now owns 288,140 shares of the medical equipment provider’s stock worth $10,571,000 after buying an additional 281,070 shares during the period. 97.56% of the stock is owned by institutional investors.
Several brokerages have weighed in on HOLX. BidaskClub lowered shares of Hologic from a “hold” rating to a “sell” rating in a research note on Saturday, January 13th. Evercore ISI began coverage on shares of Hologic in a research note on Wednesday, January 3rd. They set an “outperform” rating and a $50.00 target price for the company. Cowen raised shares of Hologic from a “market perform” rating to an “outperform” rating and set a $51.00 target price for the company in a research note on Monday, December 11th. Needham & Company LLC reaffirmed a “buy” rating and set a $50.00 target price on shares of Hologic in a research note on Friday, February 9th. Finally, Stifel Nicolaus lowered shares of Hologic from a “buy” rating to a “hold” rating and lowered their price objective for the company from $45.00 to $42.00 in a research note on Friday, February 9th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and nine have given a buy rating to the company. Hologic currently has an average rating of “Buy” and an average price target of $47.21.
In other news, Director Namal Nawana bought 6,600 shares of Hologic stock in a transaction that occurred on Tuesday, February 13th. The shares were purchased at an average price of $37.88 per share, with a total value of $250,008.00. Following the completion of the acquisition, the director now directly owns 6,954 shares in the company, valued at $263,417.52. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Charles J. Dockendorff bought 13,000 shares of Hologic stock in a transaction that occurred on Thursday, March 15th. The stock was purchased at an average cost of $38.80 per share, for a total transaction of $504,400.00. The disclosure for this purchase can be found here. 0.79% of the stock is owned by company insiders.
Shares of NASDAQ HOLX traded down $1.02 during midday trading on Friday, hitting $36.43. The company’s stock had a trading volume of 2,181,431 shares, compared to its average volume of 2,562,864. The company has a debt-to-equity ratio of 0.87, a quick ratio of 0.98 and a current ratio of 1.25. Hologic has a 1 year low of $35.33 and a 1 year high of $46.80. The firm has a market cap of $10,356.01, a price-to-earnings ratio of 17.95, a PEG ratio of 1.69 and a beta of 0.85.
Hologic (NASDAQ:HOLX) last issued its earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.50 by $0.05. The firm had revenue of $791.10 million for the quarter, compared to analysts’ expectations of $785.80 million. Hologic had a net margin of 34.53% and a return on equity of 20.07%. The firm’s revenue was up 7.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.52 earnings per share. equities analysts predict that Hologic will post 2.25 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This article was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/04/07/paloma-partners-management-co-purchases-21494-shares-of-hologic-inc-holx.html.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.